[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"venous-insufficiency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:venous-insufficiency":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,79,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100640028","assessment-of-venous-insufficiency-and-clinical-features-in-lipedema-100640028",false,"NCT07603076","Assessment of Venous Insufficiency and Clinical Features in Lipedema","Evaluation of Venous Insufficiency and Its Association With Clinical Features in Patients With Lipedema: A Cross-Sectional Study","Inclusion Criteria:\n\n* Female participants aged 18 years or older\n* Clinically diagnosed lipedema according to established diagnostic criteria\n* Ability to provide written informed consent\n* Ability to complete clinical assessments and questionnaires\n\nExclusion Criteria:\n\n* History of lower extremity venous surgery or sclerotherapy\n* Known peripheral arterial disease\n* Secondary lymphedema or other causes of lower extremity edema\n* Active infection, cellulitis, or inflammatory disease affecting the lower extremities\n* Pregnancy or postpartum period\n* Neurological, rheumatological, or musculoskeletal disorders significantly affecting lower extremity function\n* Malignancy or severe systemic disease\n* Inability to undergo venous Doppler ultrasonography\n* Inability to understand or complete study assessments and questionnaires","FEMALE","18 Years","65 Years",{"count":20,"type":21},82,"ESTIMATED","OBSERVATIONAL","Lipedema is a chronic adipose tissue disorder characterized by disproportionate fat accumulation, pain, tenderness, edema, and functional impairment. Venous symptoms such as heaviness, swelling, and discomfort are frequently reported in individuals with lipedema; however, the relationship between venous Doppler ultrasonography findings and lipedema-related clinical manifestations remains insufficiently investigated. This cross-sectional controlled study aims to evaluate venous insufficiency parameters in patients with lipedema using Doppler ultrasonography and to examine their associations with pain severity, lower extremity function, disease severity, and quality of life.",[25,26,27,28],"Lipedema","Venous Insufficiency","Venous Disease","Disability Physical","NOT_YET_RECRUITING","2026-05-17",{"date":32,"type":33},"2026-05-22","ACTUAL",{"date":35,"type":21},"2026-05-20",{"date":37,"type":21},"2026-08-01",{"name":39,"class":40},"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100626199","phase-3-design-and-rationale-of-the-colt-study-100626199","NCT07432529","Design and Rationale of the COLT Study","Design and Rationale of the COLT Study: a Multicentre, Randomised, Double-blind, Placebo-controlled Trial of COLchicine as Adjunctive Therapy to Standard Anticoagulation in Acute Proximal Deep Vein Thrombosis of the Lower Limbs","COLT","Inclusion Criteria:\n\n1. Age ≥18 years at the time of screening.\n2. Objectively confirmed first, symptomatic acute proximal lower-limb deep vein thrombosis (DVT), involving the popliteal vein or more proximal veins, diagnosed within the previous 48 hours.\n3. Planned initiation of standard anticoagulation therapy, including:\n\n   * Low-molecular-weight heparin (LMWH) bridging to vitamin K antagonists (VKA) or direct oral anticoagulants (DOACs),\n   * DOAC monotherapy according to local guidelines,\n   * Fondaparinux or other guideline-recommended regimens. Note: Standard anticoagulation regimens include dose reduction of apixaban or rivaroxaban at the sixth month, as per local practice.\n4. Ability and willingness to provide written informed consent and comply with all study procedures.\n\nExclusion Criteria:\n\nParticipants meeting any of the following criteria will be excluded:\n\n1. History of prior DVT in the same limb.\n2. Known contraindications to anticoagulation or anticipated inability to comply with study procedures.\n3. Current use of colchicine or clinical indication requiring colchicine therapy.\n4. Known hypersensitivity or allergy to colchicine.\n5. Severe hepatic impairment, defined as ALT or AST \\>3× upper limit of normal, or severe renal impairment (creatinine clearance \\\u003C30 mL\u002Fmin).\n6. Active malignancy with an estimated life expectancy \\\u003C12 months.\n7. History of active or chronic gastrointestinal disease that may interfere with colchicine tolerance, including:\n\n   1. Inflammatory bowel disease (Crohn's disease or ulcerative colitis),\n   2. Collagenous colitis,\n   3. Irritable bowel syndrome,\n   4. Chronic or recurrent diarrhea.\n8. Recent (\\\u003C30 days) or ongoing use of systemic immunosuppressive therapy, including but not limited to corticosteroids, cyclosporine, or tumor necrosis factor-alpha inhibitors.\n9. Pregnancy or breastfeeding, or unwillingness to use effective contraception during the study period.\n10. Concomitant use of strong CYP3A4 inhibitors or P-glycoprotein inhibitors contraindicated with colchicine.\n11. Major bleeding event within the past 30 days or assessed as high bleeding risk by the investigator.\n12. Inability or unwillingness to provide informed consent or to comply with study procedures.","ALL",{"count":52,"type":21},940,"INTERVENTIONAL",[55],"PHASE3","Deep vein thrombosis (DVT) is a condition in which a blood clot forms in the deep veins of the leg and can lead to long-term problems such as leg pain, swelling, and reduced quality of life. Standard treatment with blood-thinning medication lowers the risk of complications, but some patients still develop long-term damage to the veins. Inflammation is thought to play an important role in these complications.\n\nThis study will evaluate whether adding colchicine, an anti-inflammatory medication already used for other conditions, to standard anticoagulant therapy can improve outcomes in patients with acute DVT. Participants will be randomly assigned to receive either colchicine or a placebo, in addition to usual blood-thinning treatment, and will be followed for one year.\n\nThe main goal of the study is to determine whether colchicine reduces the risk of developing long-term vein problems after DVT. The study will also assess the risk of new blood clots, vein recovery, quality of life, and the safety of colchicine treatment.",[58,59,60,26],"Venous Thrombosis Deep (Limbs)","Post-thrombotic Syndrome","Venous Thromboembolism (VTE)",[62,63,64,65,66,67,68],"Deep vein thrombosis","Venous thromboembolism","Post-thrombotic syndrome","Colchicine","Anticoagulation therapy","Randomized controlled trial","Inflammation","2026-02-21",{"date":71,"type":33},"2026-02-25",{"date":73,"type":21},"2026-06-01",{"date":75,"type":21},"2027-06-01",{"name":77,"class":78},"Azienda Sanitaria Locale ASL 6, Livorno","OTHER_GOV",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":53,"phases":88,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":107},"100578485","non-healing-venous-leg-ulcers-treated-with-standard-care-with-or-without-br-ac-100578485","NCT06811909","Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC","A Prospective, Multicenter, Randomized, Controlled Trial of Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC","Inclusion Criteria:\n\n1. Patient has signed the informed consent form.\n2. Male or female patient at least 18 years of age or older, as of the date of the screening visit.\n3. Has a VLU between the knee and ankle (at or above the malleoli), with a surface area in the range of ≥ 2.0 cm2 and ≤ 20.0 cm2 when measured by the investigator staff at the screening visit using the eKare device post debridement.\n\n   1. If the subject presents with \\> 1, but ≤ 3 VLU on the same leg, the largest ulcer will be selected as the target ulcer.\n   2. If the target ulcer is \\\u003C 1cm from another VLU, the ulcers should be traced as a single target ulcer provided at least one of the ulcers is at least 2.0 cm2 in area and the total surface area of the VLUs is ≤ 20.0 cm2.\n4. Target ulcer involves a full-thickness skin loss, but without exposure of tendon, muscle, or bone.\n5. Target ulcer duration ≥ 4 weeks but ≤ 52 weeks (12 months).\n6. Venous insufficiency confirmed by duplex Doppler ultrasound examining valvular or venous incompetence.\n\n   a. Availability of a complete report of a previous examination performed 12 months of screening will be acceptable, and this examination would not be required to be repeated.\n7. Arterial supply adequacy confirmed by any one of the following:\n\n   1. Great toe pressure ≥ 50 mm\u002FHg\n   2. Systolic blood pressure Ankle Brachial Index (ABI) in the range ≥ 0.80 ≤ 1.10\n   3. TcPO2 ≥ 40 mmHg from the foot\n8. Willing to follow all instructions given by the Investigator, return for all visits, and adhere to compression protocols while on the study.\n\nExclusion Criteria:\n\n1. A target ulcer of non-venous etiologies (e.g., sickle cell anemia, necrobiosis lipoidica diabeticorum, pyoderma gangrenosum, vasculopathic or vasculitic).\n2. Acute Deep Vein Thrombosis (DVT), defined as the first 10 days from onset of symptoms, or any DVT for which compression is considered by the Investigator to be contraindicated.\n3. Clinical evidence of ulcer bed infection, or infected hardware.\n4. Documented history of osteomyelitis at the target ulcer location within six (6) months preceding the screening visit.\n5. Refusal or inability to tolerate compression therapy.\n6. Pregnant women.\n7. Women of child-bearing potential who are unwilling to avoid pregnancy or use an effective form of birth control.\n8. Hemoglobin A1c (HbA1c) level is \\> 12% (108 mmol\u002Fmol).\n9. Current therapy with systemic antibiotics.\n10. Current therapy with cytotoxic agents.\n11. Current therapy with chronic (\\> 10 days) oral corticosteroids.\n12. Current therapy with TNFα inhibitors other than Trental® (pentoxifylline).\n13. Has tested positive for Human Immunodeficiency Virus (HIV) or has Acquired Immune Deficiency Syndrome (AIDS).\n14. Has malignancy or history of cancer in the preceding 5 years other than non-melanoma skin cancer.\n15. Currently on dialysis or planning to start dialysis.\n16. Is currently enrolled or participated in another device, drug, or biological trial within 30 days of screening.\n17. Therapy of the target ulcer with other birth tissue products, autologous skin graft, Apligraf®, or Dermagraft® within 30 days preceding the screening visit.\n18. Therapy of the target ulcer with topical growth factors within thirty (30) days preceding the screening visit.\n19. Any previous use of Vendaje®, Vendaje AC®, AmnioWrap2® applied to the target ulcer.",{"count":87,"type":21},60,[89],"NA","This study examines a patient population with a non-healing, non-infected venous leg ulcer (VLU) having adequate arterial perfusion with confirmed venous reflux. It is hypothesized that weekly applications of the human placental allograft BioREtain® Amnion Chorion (BR-AC) applied to a non-healing VLU will result in a higher proportion of wounds showing complete healing within 12 weeks of initiating therapy, compared to standard care alone.\n\nThis study has a crossover period, where subjects on standard care alone who do not achieve complete healing within 12 weeks of initiating therapy will be allowed to crossover to receive BR-AC over 12 additional weeks, to evaluate if their wound can achieve complete healing.",[92,93,26,94,95],"Non-infected Venous Leg Ulcer","Venous Leg Ulcer","Venous Stasis","Venous Reflux","RECRUITING","2026-01-21",{"date":99,"type":33},"2026-01-23",{"date":101,"type":33},"2025-02-14",{"date":103,"type":21},"2026-10",{"name":105,"class":106},"BioStem Technologies","INDUSTRY",23,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":53,"phases":117,"briefSummary":118,"conditions":119,"keywords":123,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":41},"100543040","the-role-of-compression-stockings-in-heart-failure-patients-100543040","NCT06350695","The ROle of Compression StocKings in Heart Failure Patients","ROCK-HF","Inclusion Criteria:\n\n* Age 18 years and older\n* Diagnosis of Heart failure NYHA II-III Class A, B, or C.\n* Pitting edema of the lower extremities\n\nExclusion Criteria:\n\n* Peripheral arterial disease with ABI of 0.5 or less\n* Severe decompensated heart failure NYHA IV\n* Unstable acute coronary syndrome\n* Severe valvular stenosis or regurgitation\n* Hypertrophic obstructive cardiomyopathy\n* Unstable arrhythmia without a defibrillator\n* On renal replacement therapy, hemodialysis of peritoneal dialysis\n* Morbid obesity with a BMI \\> 40\n* Pregnancy\n* Lymphedema or Lipoedema\n* Unable to put the compression stockings on by him\u002F herself or a person to do it for the patient\n* Septic phlebitis, acute bacterial, viral or allergic inflammation of the legs\n* Expectancy of life less than 6 months\n* Unable to read or understand English language",{"count":116,"type":21},50,[89],"Congestive heart failure (CHF) occurs when the heart is weak and not able to effectively pump blood to the body. One of the common manifestations of CHF is fluid overload and swelling of the legs. Diuretics or \"water pills\" are usually the treatment for fluid overload and leg swelling; however, in some patients' diuretics are no longer effective or the effectiveness is limited due to poor kidney function. The presence of chronic swelling of the legs could potentially damage the veins; additionally, it could lead to chronic skin changes in the legs and in the worst cases to a leg ulcer. Compression stockings are used in patients with venous diseases to reduce the swelling of the legs and improve mobility and quality of life. Although, there is a theoretical risk that compression stockings might push the fluid of the legs back to the heart and lungs worsening the CHF. The purpose of this study is to determine whether the use of knee-high tight socks (tight stockings with strong compression) vs. knee-high soft socks (soft stockings with minimum compression) are effective in preventing swelling and skin changes and safe in patients with CHF. During the first visit (in-person) a routine medical test will be performed including blood tests, review of the medication doses, current weight, an ultrasound images of the veins, (venous reflux ultrasound), questions about health status and a brief physical exam. The participants will be randomly assigned to receive tight compression vs. soft compression socks. Participants will be asked to wear the socks at least 8 hours a day for 5 days a week. There will be a total of 3 virtual visit (by video or telephone); the first one after one week, then after one month and two months. During the virtual visit participants will be asked about symptoms, current medications and doses, and current weight. The participants are expected to return to the clinic after 3 months for a second in-person visit. During this visit the investigators will ask questions about participant's health, they will perform a brief physical exam of their legs, and check participants weight and medicines; also, a venous ultrasound of the legs, questions about health status will be performed. The duration of the study is 3 months.",[120,121,26,122],"Heart Failure，Congestive","Leg Edema","Venous Ulcers",[124,125,126,127,128],"compression stockings","congestive heart failure","venous insufficiency","edema of the legs","venous ulcers","2024-09-30",{"date":131,"type":33},"2024-10-02",{"date":133,"type":33},"2024-01-17",{"date":135,"type":21},"2026-01-01",{"name":137,"class":40},"University of Maryland, Baltimore"]